Skip to main content
Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.
- Landovitz, Raphael J;
- Zangeneh, Sahar Z;
- Chau, Gordon;
- Grinsztejn, Beatriz;
- Eron, Joseph J;
- Dawood, Halima;
- Magnus, Manya;
- Liu, Albert Y;
- Panchia, Ravindre;
- Hosseinipour, Mina C;
- Kofron, Ryan;
- Margolis, David A;
- Rinehart, Alex;
- Adeyeye, Adeola;
- Burns, David;
- McCauley, Marybeth;
- Cohen, Myron S;
- Currier, Judith S
- et al.
Published Web Location
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938971/pdf/ciz439.pdfNo data is associated with this publication.
Abstract
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.